HC Wainwright Reaffirms Neutral Rating for AnaptysBio (NASDAQ:ANAB)

HC Wainwright reaffirmed their neutral rating on shares of AnaptysBio (NASDAQ:ANAB - Free Report) in a research report released on Tuesday morning,Benzinga reports. HC Wainwright currently has a $22.00 target price on the biotechnology company's stock.

Other equities research analysts also recently issued reports about the stock. JPMorgan Chase & Co. decreased their price target on shares of AnaptysBio from $66.00 to $36.00 and set an "overweight" rating for the company in a research note on Thursday, December 19th. Wedbush reaffirmed an "outperform" rating and set a $40.00 price target on shares of AnaptysBio in a research note on Wednesday, February 12th. Truist Financial reduced their price objective on AnaptysBio from $30.00 to $20.00 and set a "hold" rating for the company in a research note on Wednesday, December 18th. BTIG Research downgraded AnaptysBio from a "buy" rating to a "neutral" rating in a report on Monday, December 2nd. Finally, Guggenheim cut their target price on AnaptysBio from $90.00 to $36.00 and set a "buy" rating on the stock in a report on Thursday, December 12th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, AnaptysBio has an average rating of "Moderate Buy" and an average price target of $35.11.

Remove Ads

AnaptysBio Trading Down 0.4 %

NASDAQ ANAB traded down $0.06 during trading hours on Tuesday, hitting $16.34. 593,252 shares of the company's stock were exchanged, compared to its average volume of 1,048,744. The firm has a market cap of $497.21 million and a price-to-earnings ratio of -2.69. The stock has a 50-day simple moving average of $16.16 and a 200 day simple moving average of $24.22. AnaptysBio has a 1-year low of $12.21 and a 1-year high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.72) EPS for the quarter, topping the consensus estimate of ($1.61) by $0.89. The company had revenue of $43.11 million during the quarter, compared to the consensus estimate of $10.17 million. AnaptysBio had a negative net margin of 289.75% and a negative return on equity of 287.94%. On average, sell-side analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

Insider Activity at AnaptysBio

In other news, Director Ecor1 Capital, Llc bought 6,646 shares of AnaptysBio stock in a transaction dated Thursday, January 2nd. The stock was purchased at an average price of $12.95 per share, for a total transaction of $86,065.70. Following the purchase, the director now directly owns 7,880,094 shares in the company, valued at $102,047,217.30. The trade was a 0.08 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 33.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ANAB. FMR LLC grew its position in AnaptysBio by 15.3% in the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company's stock worth $110,857,000 after purchasing an additional 438,557 shares in the last quarter. Frazier Life Sciences Management L.P. grew its holdings in shares of AnaptysBio by 2.0% in the third quarter. Frazier Life Sciences Management L.P. now owns 2,209,189 shares of the biotechnology company's stock valued at $74,008,000 after acquiring an additional 43,598 shares in the last quarter. Vanguard Group Inc. increased its position in shares of AnaptysBio by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 1,843,740 shares of the biotechnology company's stock valued at $24,411,000 after acquiring an additional 143,584 shares during the last quarter. Fairmount Funds Management LLC purchased a new stake in shares of AnaptysBio during the fourth quarter valued at approximately $24,050,000. Finally, Boxer Capital Management LLC bought a new stake in AnaptysBio during the fourth quarter worth $17,212,000.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.